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5-ﬂuorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer
(CRC) treatment. Because chemoresistance occurs frequently and signiﬁcantly limits CRC therapies, a
novel agent is needed. Pseudolaric acid B (PAB), a small molecule derived from the Chinese medicinal
herb ‘‘Tujinpi’’, exhibits strong cytotoxic effects on a variety of cancers. However, the detailed mecha-
nisms by which PAB inhibits CRC cell growth and its potential role in overcoming 5-FU resistance have
not been well studied. In this study, we showed that PAB signiﬁcantly inhibited the viability of various
CRC cell lines but induced minor cytotoxicity in normal cells. Both the in vitro and in vivo results showed
that PAB induced proliferation inhibition, mitotic arrest and subsequently caspase-dependent apoptosis
in both 5-FU-sensitive and -resistant CRC cells. Moreover, PAB was shown to interfere with CRC cell
mitotic spindle apparatus and activate the spindle assembly checkpoint. Finally, CDK1 activity was
involved in PAB-induced mitotic arrest and apoptosis in CRC cells. Taken together, these data reveal that
PAB induces CRC cell mitotic arrest followed by apoptosis and overcomes 5-FU resistance in vitro and
in vivo, suggesting that PAB may be a potential agent for CRC treatment, particularly for 5-FU-resistant
CRC.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Colorectal cancer (CRC) is the third most common cancer
worldwide [1]. Surgery and chemotherapy are twomajor treatment
options for CRC patients, and 5-ﬂuorouracil (5-FU)-based chemo-
therapy is still the main chemotherapeutic approach in these pa-
tients. 5-FU-based chemotherapy has yielded a signiﬁcant
prolongation of survival. However, 5-FU resistance occursx: þ86 20 38254221.
x: þ86 20 38254221.
iu), yangxl28@mail.sysu.edu.
ch and Development (AMED),
Ireland Ltd. This is an open accessfrequently and results in a high level of treatment failure in CRC
patients [2e4]. Therefore, novel agents are needed in order to in-
crease the treatment efﬁcacy and overcome 5-FU resistance.
Nearly 51% of the approved drugs in cancer therapeutics intro-
duced from 1981 to 2014 were of natural origin [5]. And an
increasing number of traditional Chinese medicines from natural
products have been recently veriﬁed to have strong anti-cancer
effects and induce fewer side effects [5,6]. Therefore, the explora-
tion of efﬁcient anti-cancer drugs from Chinese medicines has
become an attractive strategy. The Chinese medicinal herb
‘‘Tujinpi’’ is from the root and trunk bark of a tree named Pseudo-
larix kaempferi Gorden (Pinaceae) from central China [7]. This me-
dicinal herb has been used to treat skin inﬂammation for several
centuries in China. The diterpene acid pseudolaric acid B (PAB),
shown in Fig. S1, is a major biologically active component inarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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fertility properties. However, recent studies have shown that PAB
has strong cytotoxic effects on various types of cancers, including
CRC, gastric cancer, liver cancer, prostate cancer, lung cancer, cer-
vical cancer, breast cancer, melanoma, and leukemia [9e11].
Although PAB exhibits cytotoxic effects on a variety of cancers,
detailed mechanisms underlying its anti-cancer activity are still
obscure. Molecular mechanisms related to effects of PAB in cancer
may be diverse and cancer-related, and may involve the MAPK
pathway, PI3K/AKT pathway, PPARg, PKC, BCL-2 family proteins,
caspase family proteins, cyclin B1/CDK1 complex and p53 [12e17].
In CRC, studies showed that PAB inhibited the growth of several CRC
cell lines including HT-29, HCT-8, SW620 and Lovo [9,18], indicating
its potential efﬁcacy for CRC therapy. Additionally, it was reported
that PAB could induce apoptosis and circumvent multiple drug
resistance (MDR) in the MDR gastric cancer cell line and MDR liver
cancer cell line [9,11]. Since resistance to 5-FU is one of most
common phenotypes in MDR, PAB could be a promising medicinal
compound to overcome 5-FU resistance in CRC cells. However,
neither the detailed mechanisms underlying the inhibition of CRC
growth by PAB nor the efﬁcacies of PAB on 5-FU resistant CRC were
investigated.
In the present study, we showed that PAB selectively inhibited
the growth of various CRC cell lines and induced both 5-FU-sensi-
tive and -resistant CRC cell proliferation inhibition, mitotic arrest
and subsequently caspase-dependent apoptosis in both in vitro and
in vivo experiments. Moreover, PAB perturbed microtubule orga-
nization and activated the spindle assembly checkpoint (SAC) of
CRC cells. Finally, we showed that CDK1 activity was involved in the
effects of PAB in CRC cells. Thus, PAB may be a potential compound
for CRC treatment, particularly for 5-FU-resistant CRC.
Materials and methods
Cell culture
Colorectal cancer cell lines HCT116, HT-29, SW620, SW480, DLD-1, HCT-8, RKO
and HCT-15 cells were purchased from the Culture Collection of Chinese Academy of
Science (Shanghai, China). Human colon epithelial cell line NCM460 was provided
by Professor Dan Xie from State Key Laboratory of Oncology in South China, Cancer
Center, Sun Yat-sen University (Guangzhou, Guangdong, China). The 5-FU-resistant
cell lines (RKO/5FU-R and HCT-15/5FU-R) were established as previously described
[19]. Brieﬂy, parental cell lines RKO and HCT-15 were stepwise exposure to
increasing concentrations of 5-FU, starting at 1 mM and ending at 100 mM. 5-FU
(1 mM) was included in the culture medium for RKO/5FU-R and HCT-15/5FU-R to
maintain the drug resistance. The cells were maintained in 5-FU free medium at
least 2 weeks before the experiments. Human peripheral blood mononuclear cells
(PBMC) were isolated from the venous blood of healthy adult volunteer donors by
standard density-gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Life
Sciences, Pittsburgh, PA, USA). HCT116, HT-29, SW620, SW480, DLD-1, HCT-8 and
PBMC were maintained in RPMI 1640 (Gibco Life Technologies, Carlsbad, CA, USA).
RKO, HCT-15, RKO/5FU-R, HCT-15/5FU-R and NCM460 were maintained in DMEM
(Gibco Life Technologies). All culture media were supplemented with 10% inacti-
vated fetal bovine serum (Gibco Life Technologies), 100 units/ml penicillin and
10 mg/ml streptomycin (Gibco Life Technologies) in a humidiﬁed atmosphere of 5%
CO2 at 37 C.
Reagents
PAB was purchased from Baoji Herbest Bio-Tech Co., Ltd. (Baoji, Shanxi, China)
with isolation from the methanol extract of the root and trunk bark of Pseudolarix
kaempferi by column chromatography and recrystallization. The purity of PAB was
>98% as determined by high-performance liquid chromatography (HPLC). PAB was
dissolved in dimethyl sulphoxide (DMSO) to a 50 mM stock solution and stored
at 20 C. 5-FU (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in DMSO to a
200 mM solution and stored at 20 C. z-VAD-fmk (Enzo, New York, USA) was
dissolved in DMSO to a 50 mM solution and stored at 20 C. RO-3306 and pur-
valanol A (Selleck Chemicals, Houston, TX, USA) were dissolved in DMSO to a 10 mM
solution and stored at 20 C. PARP, caspase3, cleaved-caspase3, caspase8, MCL-1,
BCL-XL, BCL-2, BAX and XIAP were from Cell Signaling Technology (Beverly, MA,
USA). Antibodies against phospho-histone h3 at Ser10 and phospho-CDK1 at Thr161
were from Signalway Antibody (Baltimore, MD, USA). a-tubulin and cleaved-
caspase9 were purchased from Abcam (Cambridge, MA, USA). Antibodies against
caspase9, cytochrome c, Cox-4, cyclin B1, BUBR1, b-actin and anti-mouseimmunoglobulin G and anti-rabbit immunoglobulin G horseradish peroxidase
conjugated secondary antibodies were from Proteintech Group (Chicago, IL, USA).
Goat anti-rabbit Alexa 488-conjugated secondary antibody was from Life Technol-
ogies (Carlsbad, CA, USA).
Cell proliferation assay by real-time cell impedance analysis
xCELLigence system (Roche Applied Science, Mannheim, Baden-Wuerttemberg,
Germany) was applied to dynamically monitor cell proliferation rates. The standard
protocol developed by Roche Applied Science was used to perform the experiment.
Brieﬂy, cells were seeded into 100 ml of media in an E-Plate. Cell proliferation was
monitored at set intervals via measuring electrical impedance across microelec-
trodes on the bottom of E-Plate. The impedance was expressed as cell index (CI), an
arbitrary unit. Real-time cell analysis (RTCA) software, supplied by the manufac-
turer, was used to analyze the measurements.
Cell viability assay
The effect of PAB on cell viability assay was analyzed by MTS assay (Promega,
Madison, WI, USA). Brieﬂy, a total of 5  104/ml cells in 100 ml were treated with
various doses PAB for 72 h, and then 20 ml MTS labeling mixture (MTS/PMS) was
added to each well and incubated for another 4 h. The absorbance density was read
on a 96-well plate reader (Thermo Fisher Scientiﬁc, Waltham, MA, USA) at wave-
length 490 nm.
Colony formation assay
Cells were seeded in a 6-well plate (500 cells/well). Cells were treated with
different concentration of PAB and cultured in an atmosphere of 5% CO2 at 37 C for 9
days. Medium was changed every 3 days. Cells were then washed with phosphate
buffer saline (PBS), ﬁxed in ice-cold methanol for 5 min, and stained with crystal
violet. Images of the colonies were obtained using an Epson scanner (Suwa, Nagano,
Japan). Representative images are shown.
Cell cycle analysis by ﬂow cytometry
Cells were treated with PAB for the indicated times. And then cells were
collected, washed and ﬁxed with 66% cold ethanol at 4 C overnight. In the next day,
cells were washed twice in PBS after 66% ethanol was moved and labeled with
propidium iodide (BD Biosciences, Franklin Lakes, NJ, USA). The cell cycle distribu-
tion was analyzed by BD FACSCanto II ﬂow cytometry (Franklin Lakes, NJ, USA).
Western blot analysis
Western blot analysis was performed as previously described [19]. Total cell
lysates were prepared in RIPA lysis buffer (Cell Signaling Technology, Beverly, MA,
USA) containing protease and phosphatase inhibitors (Nanjing KeyGen Biotech Co.,
Ltd., Nanjing, Jiangsu, China). The cytosolic and mitochondrial fractions were iso-
lated by the cytoplasmic protein extraction kit and the mitochondrial protein
extraction kit (Nanjing KeyGen Biotech Co., Ltd.). Protein concentrations were
measured using a Pierce BCA protein assay kit (Thermo Fisher Scientiﬁc, Waltham,
MA, USA). Proteins were separated by SDS-PAGE and transferred to PVDF mem-
branes followed by probed with a primary antibody overnight at 4 C. The next day,
themembranewaswashed and incubatedwith HRP-conjugated secondary antibody
at room temperature for 1 h followed by ECL detection. After detection of protein
bands, the membrane was stripped and re-probed with anti-b-actin or anti-Cox-4
antibody to conﬁrm equal loading of samples.
Analysis of cell apoptosis by ﬂow cytometry
Apoptosis was determined by ﬂow cytometry using an Annexin V-FITC/propi-
dium iodide (PI) staining kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, Jiangsu,
China). Cells were treated with PAB for the indicated times. After PAB treatment,
cells were collected, washed and stained in working solution (500 ml binding buffer
with 5 ml Annexin V-FITC and 5 ml PI) for 15 min at room temperature in the dark.
Apoptotic cells were determined by BD FACSCanto II ﬂow cytometry (Franklin Lakes,
NJ, USA). Annexin V-FITC-positive and Annexin V-FITC-plus-PI positive cells were
determined as apoptotic cells.
Mitochondrial membrane potential measurement
Mitochondrial membrane potential was detected using a JC-1 mitochondrial
membrane potential assay kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, Jiangsu,
China), following the manufacturer's protocol. Brieﬂy, after PAB treatment, cells
were washed twice in PBS, incubated with JC-1 staining solution at 37 C for 20 min
and rinsed twice with incubation buffer provided by the kit. Fluorescence intensity
of both mitochondrial JC-1 monomers (Green) and aggregates (Red) were detected
using a BD FACSCanto II ﬂow cytometry (Franklin Lakes, NJ, USA). JC-1 stains the
mitochondria of healthy cells red only.
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Cells grown on glass coverslips and treated with PAB for 12 h were washed with
PBS, ﬁxed for 20 min with 3% paraformaldehyde, permeabilized for 15 min with 1%
Triton X-100 and 0.5% NP-40, and blocked for 1 h with 5% bovine serum albumin, all
at room temperature. Immunoﬂuorescent staining was performed using a-tubulin
as primary antibodies, which were detected via goat anti-rabbit Alexa 488-
conjugated secondary antibody. Images were captured using a Leica TCS-SP8
confocal microscope (Mannheim, Baden-Wuerttemberg, Germany).
Nude mouse xenograft model
Five-week-oldmale BALB/c nudemicewere bred at Experimental Animal Center
at Sun Yat-sen University. A total of 1  107 of HCT-15 or HCT-15/5FU-R cells was
inoculated subcutaneously on the ﬂanks of nude mice. After 5 days of inoculation,
mice were treated with vehicle (10% DMSO, 20% cremophor and 70% NaCl, i.p.) and
PAB (50 mg/kg/d, i.p.) for a total of 22 days and 28 days in HCT-15 and HCT-15/5FU-R
group, respectively. Tumors were measured every other days and the formula:
a2 b 0.4, where a is the smallest diameter and b is the diameter perpendicular to
a, was used to calculate tumor volumes. At the end of the study, tumors from
sacriﬁced mice were removed, weighed and stored. All animal studies were con-
ducted with the approval of the Institutional Animal Care and Use Committee of Sun
Yat-sen University.
Statistical analysis
All experiments were performed at least 3 times, and results were demonstrated
as mean ± SD where applicable. Statistical analysis was performed by one-way
analysis of variance followed by Tukey's test by GraphPad Prism software (San
Diego, CA, USA). P < 0.05 was considered statistically signiﬁcant.
Results
PAB inhibits proliferation and induces mitotic arrest in CRC cells
Previously studies reported that PAB exerted the cytotoxic ef-
fects on the CRC cell lines HT-29, HCT-8, SW620 and Lovo. First, we
tested its cytotoxic effects on a broad range of CRC cell lines by MTS
assay. After 72 h of PAB treatment, the viability of various CRC cell
lines was signiﬁcantly inhibited (Table 1). Effective anti-cancer
compounds need to selectively kill cancer cells with minimal ef-
fects on normal cells. Results in this study showed that the cyto-
toxicity of PAB for human colon epithelial cell line NCM460was less
than its cytotoxicity for CRC cells, as the IC50 of PAB for
NCM460 cells was up to 8.49 mM. Moreover, PAB induced few
cytotoxic effects in normal PBMC from three healthy volunteers
with IC50 values of more than 20 mM. Taken together, these data
suggest that PAB selectively inhibits the growth activity of CRC cells.
RKO (p53 wild-type) and HCT-15 (p53 mutated) [20,21] were
chosen as representative cell lines to further study. Real-time cell
analysis and colony formation assay were then performed to
investigate the effect of PAB on CRC cell proliferation. As shown in
Fig. 1A and B, both the cell index and colonies were inhibited by
PAB in a dose-dependent manner in RKO and HCT-15 cells, indi-
cating that CRC cell proliferation is signiﬁcantly restrained. ToTable 1
Effects on viability of PAB to various CRC cells and
normal cells.
Cell line IC50(mM)
HCT116 0.54
HT-29 3.43
SW620 1.16
SW480 4.52
DLD-1 0.57
HCT-8 0.39
HCT-15 1.20
RKO 0.84
NCM460 8.49
PBMC-1 101.50
PBMC-2 24.57
PBMC-3 73.24determine whether the cell cycle arrest was related to the anti-
proliferative effects of PAB, RKO and HCT-15 cells were treated
with PAB at 1 mM and 2 mM, respectively, to assess the cell cycle
distribution by ﬂow cytometry. The proportion of RKO and HCT-
15 cells at the G2/M phase increased substantially from 21.21% and
25.20% to 55.17% and 49.50%, respectively, after 12 h of PAB treat-
ment (Fig. 1C). To determine whether cells were arrested specif-
ically in G2 or mitosis, we investigated the expression of cyclin B1
and p-histone h3 proteins; the expression levels of these proteins
increase during mitosis and thus they can serve as indicators of
mitotic progression [22,23]. Results presented in Fig. 1D demon-
strated that the addition of PAB increased cyclin B1 and p-histone
h3 expression, indicating that PAB causes mitotic arrest in CRC cells.
PAB also induced mitotic arrest in synchronous RKO and HCT-
15 cells (Fig. S2).
PAB induces CRC cell caspase-dependent apoptosis
As shown in Fig. 1C, the sub-G1 cell population increased after
12 h of PAB treatment in both cell lines, suggesting that PAB may
induce apoptotic cell death. Several experiments were performed
to test the above hypothesis. Initially, CRC cells were assessed by
ﬂow cytometry with Annexin V-FITC/PI staining after PAB expo-
sure. PAB resulted in apoptotic cell populations that increased in a
time-dependent manner (Fig. 2A). Moreover, western blot analysis
showed that PAB induced PARP cleavage (an indicator of apoptosis)
in a dose- and time-dependent manner in both cell lines (Fig. 2B).
Caspase family proteins, which are upstream proteins of PARP, were
also activated. Levels of the precursor forms of caspase3, 8, and 9
were decreased and the cleaved forms of caspase3, 8, and 9 were
increased after PAB treatment (Fig. 2B), indicating that caspase
activation may be required for PAB-induced CRC cell apoptosis.
Mitochondrial damage, which involves a number of events
including the loss of mitochondrial membrane potential (MMP),
mitochondrial swelling and the release of mitochondrial proteins
such as cytochrome c from mitochondria to the cytosol, can induce
the onset of apoptosis [24]. As shown in Fig. 2C, the PAB-induced
loss of MMP in RKO and HCT-15 cells increased in a time-
dependent manner. Consistently, cytosolic levels of cytochrome c
increased while mitochondrial levels of cytochrome c decreased
(Fig. 2D). Because the apoptosis can be affected by IAP and BCL-2
family proteins [25,26], the expression of IAP and BCL-2 family
proteins was measured. Western blot analysis revealed that XIAP,
MCL-1, BCL-2 and BCL-XL expression levels decreased in a dose-
and time-dependent manner, but BAX expression levels were up-
regulated (Fig. 2E). Taken together, these results demonstrate that
PAB induces CRC cell apoptosis. PAB also up-regulated the expres-
sion of cleaved-caspase3 and cleaved-PARP in synchronous RKO
and HCT-15 cells (Fig. S2B), indicating the effect of PAB in inducing
CRC cell apoptotic death again. To conﬁrm that the PAB-induced
apoptosis in CRC cells was caspase-dependent, CRC cells were
analyzed to assess apoptosis after treatment with PAB and the pan-
caspase inhibitor z-VAD-fmk. The induction of apoptotic cell pop-
ulations by PAB was signiﬁcantly inhibited by z-VAD-fmk in both
RKO and HCT-15 cells (Fig. 3A and S3), suggesting that the apoptotic
event induced by PAB in CRC cells is caspase-dependent. However,
z-VAD-fmk did not prevent mitotic arrest (Fig. 3B), indicating that
cell cycle arrest induced by PAB may be an early event and
apoptosis-independent.
PAB interferes with the mitotic spindle apparatus and activates the
spindle assembly checkpoint of CRC cells
Most agents that induce mitotic arrest are shown to interfere
with mitotic spindle apparatus [27,28]. To evaluate whether PAB
Fig. 1. PAB inhibits proliferation and induces mitotic arrest in RKO and HCT-15 cells. (A) The proliferation of RKO and HCT-15 cells was measured by real-time cell analysis.
Mean ± SD (n ¼ 3). **P < 0.01, ***P < 0.001, versus control group. (B) The colony formation of RKO and HCT-15 cells was counted after cells were treated with indicated con-
centrations of PAB for 9 days and then were washed, ﬁxed, and stained with crystal violet. Mean ± SD (n ¼ 3). *P < 0.05, ***P < 0.001. (C) RKO and HCT-15 cells were stained with PI
for DNA contents, followed by ﬂow cytometric analysis. Mean ± SD (n ¼ 3). ***P < 0.001. (D) Expression levels of cyclin B1 and p-histone h3 in RKO and HCT-15 were detected by
western blot analysis. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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tubulin in RKO and HCT-15 cells and evaluated the cells using
immunoﬂuorescence. As shown in Fig. 4A, few abnormal spindles
were detected in the untreated mitotic cells, whereas the aberrant
mitotic spindle morphology increased in the mitotic CRC cells
cultured with PAB, indicating that PAB can trigger the abnormal
spindle formation in CRC cells. Moreover, a substantial increase in
the proportion of cells in the prometaphase was found after 12 h of
PAB treatment, whereas all four mitotic phases could be readily
found in the untreated control (Fig. 4B). The spindle assembly
checkpoint (SAC) ensures correct mitotic progression. Once the
mitotic apparatus is disturbed in early mitosis, the SAC will be
continually activated and induce cells arrest prior to anaphase [29].
Therefore, we investigated whether PAB activated the SAC by
evaluating the expression of phosphorylated (mobility shifted)
BUBR1, a core component of the SAC. As shown in Fig. 4C, the p-
BUBR1 expression in CRC cells was up-regulated under PAB stim-
ulation, indicating that the SAC is activated by PAB. Taken together,
our data demonstrate that PAB can arrest cell cycle progression in
themitotic phase (speciﬁcally in prometaphase) by interfering with
the mitotic spindle apparatus and activating the SAC of CRC cells.
CDK1 is involved in PAB-induced mitotic arrest and apoptosis in CRC
cells
The CDK1 activity plays important roles in mitosis progression
[29]. Additionally, CDK1 was recently shown to participate in the
apoptotic cell death induced by anti-mitotic agents [30]. Hence, we
investigated the role of CDK1 in the effect of PAB in CRC cells. To
investigate the effect of CDK1 in mitosis, CRC cells should ﬁrst be
accumulated in mitosis. As shown in Fig. 1C, D and S2, most of the
cells accumulated in mitosis after 12 h of PAB treatment or 6 h after
release from a double thymidine block. After 12 h of PAB treatment,
cells were continuously treated with PAB in the absence and
presence of RO-3306 or purvalanol A, the selective CDK1 inhibitor,
for 12 h and 36 h to detect the effects of CDK1 on the cell cycle and
cell death, respectively. The expression of p-histone h3 at 12 h and
the expression of cleaved-PARP and cleaved-caspase3 at 36 h were
signiﬁcantly up-regulated by PAB in CRC cells; however, RO-3306
and purvalanol A could reverse these changes (Fig. 5A and B).
Similar results were observed in the double thymidine block group
(Fig. S4). Together, these data provide evidence that the activity of
CDK1 is involved in PAB-induced CRC cell mitotic arrest and
apoptosis.
PAB induces mitotic arrest and apoptosis in 5-FU-resistant CRC cells
The effect of PAB in overcoming 5-FU resistance in CRC cells was
investigated in this study. 5-FU-resistant CRC cells, RKO/5FU-R and
HCT-15/5FU-R cells were well established by our group (Fig. S5)
[19]. Cell viability was initially determined using the MTS assay. As
shown in Fig. 6A, PAB inhibited RKO/5FU-R and HCT-15/5FU-R cell
growth with IC50 values of 0.82 mM and 2.74 mM, respectively. The
colony formation assay showed that the proliferation of RKO/5FU-R
and HCT-15/5FU-R cells was inhibited by PAB in a dose-dependent
manner (Fig. 6B). Results presented in Fig. 6C and D showed that
PAB arrested RKO/5FU-R and HCT-15/5FU-R cells in mitotic phase,
which was consistent with the cell cycle disturbance of their
parental cell lines in response to PAB. Time-dependent apoptotic
cell death was also observed in RKO/5FU-R and HCT-15/5FU-R cells
exposed to PAB through ﬂow cytometry with Annexin V-FITC/PI
staining (Fig. 7A). Western blot analysis of apoptosis-related pro-
teins and the ﬂow cytometry analysis of MMP in RKO/5FU-R and
HCT-15/5FU-R cells treated with PAB conﬁrmed that PAB induced
RKO/5FU-R and HCT-15/5FU-R cell apoptosis (Fig. 7BeE). Takentogether, these results demonstrate that PAB can circumvent 5-FU
resistance in CRC cells.
PAB inhibits growth in both 5-FU-sensitive and -resistant CRC cell
xenografts
Finally, we examined the effects of PAB in vivo using a nude
mouse xenograft model. In the in vivo model, HCT-15 and HCT-15/
5FU-R cells were inoculated subcutaneously into nude mice. Then,
mice in the HCT-15 and HCT-15/5FU-R groups were treated with
vehicle and PAB (50 mg/kg/d) by intraperitoneal injection for 22
and 28 days, respectively. PAB treatment signiﬁcantly reduced tu-
mor volumes and tumor weights in both HCT-15 and HCT-15/5FU-R
xenografts (Fig. 8A and B), indicating that the growth of both HCT-
15 and HCT-15/5FU-R xenografts is inhibited by PAB. Pro-caspase3
protein levels were decreased signiﬁcantly whereas p-histone h3,
cyclin B1 and p-CDK1 protein levels were increased in PAB-treated
tumors versus the control (Fig. 8C), which was consistent with the
in vitro data. Moreover, signiﬁcant losses were not detected in the
body weights of the experimental animals and PAB did not harm
animals' livers based on H&E staining of that organ (Fig. 8D and E),
suggesting that PAB has no major side effects in mice.
Discussion
CRC is one of the most common and high mortality cancers
worldwide. 5-FU-based chemotherapy remains the main treatment
option for CRC patients but resistance to 5-FU happens very often.
Recently, molecular targeted agents such as bevacizumab, cetux-
imab and panitumumab have been used for CRC treatment [31e33].
However, the effects of these drugs are not very satisfactory and
thus novel agents are needed for CRC treatment. Some traditional
Chinese medicines have been shown to have outstanding anti-
cancer effects with fewer side effects. For instance, gambogic acid
extracted from the traditional Chinese medicine gamboges was
shown to have a strong cytotoxic effect on a broad range of tumors
with few effects on the hematologic system and was approved by
the China Food and Drug Administration for a phase III clinical trial
in solid cancer therapy [34,35]. Another Chinese medicine (pseu-
dolaric acid B, PAB) has drawn people's attention recently. Over the
past few years PAB was discovered to have a strong cytotoxic effect
against a broad range of human cancer cells and minor toxicity in
normal cells [7e10,36,37]. The present study investigated the effect
of PAB in both 5-FU-sensitive and -resistant CRC cell lines. PAB
induced mitotic arrest followed by caspase-dependent apoptosis
in vitro in both 5-FU-sensitive and -resistant CRC cells but had
minimal effects in normal cells. The in vivo experiment showed that
both 5-FU-sensitive and -resistant xenografted CRCs were sensitive
to PAB treatment.
Almost all studies have shown that PAB causes cell arrest in G2/
M, but mechanisms by which PAB induces cell death are diverse.
For example, Yu et al. showed that PAB induced senescence in
murine ﬁbrosarcoma cell line L929, whereas Li et al. indicated that
PAB directly caused apoptosis in human cervical cancer HeLa cell
line [38,39]. Moreover, the apoptosis induced by PAB can be
caspase-dependent or caspase-independent [40,41]. In the present
study, we showed that PAB inhibited proliferation and induced
mitotic arrest in both 5-FU-sensitive and -resistant CRC cells.
Additionally, PAB activated caspase8 and triggered the loss of MMP
followed by the release of cytochrome c to the cytosol, which
subsequently activated caspase9. These results indicate that PAB
causes apoptosis, which may require the caspase activation, in CRC
cells. The general caspase inhibitor z-VAD-fmk almost abolished
the PAB-induced apoptotic effect, conﬁrming that PAB-induced
apoptosis in CRC cells is caspase-dependent. However, as the z-
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Fig. 3. Caspase activation is required for the apoptosis but has no effect in mitotic arrest induced by PAB in CRC cells. (A) RKO and HCT-15 cells were treated with PAB for 48 h and
72 h, respectively, in the absence and presence of 50 mM pan-caspase inhibitor z-VAD-fmk and then apoptotic cell populations were analyzed by ﬂow cytometry. Mean ± SD (n ¼ 3).
***P < 0.001. (B) RKO and HCT-15 cells were treated with PAB for 24 h in the absence and presence of 50 mM pan-caspase inhibitor z-VAD-fmk and stained with PI for DNA contents,
followed by ﬂow cytometric analysis.
C. Wen et al. / Cancer Letters 383 (2016) 295e308 301VAD-fmk did not prevent mitotic arrest and mitotic arrest occurred
earlier than apoptosis, the mitotic arrest induced by PAB was most
likely an early event and apoptosis-independent.
Cancer cells undergo two main outcomes after they are arrested
in mitosis by anti-mitotic compounds like paclitaxel or vincristine:
some cells die in mitosis, whereas others exit mitosis and return to
interphase without dividing, knowing as mitotic ‘slippage’ [42,43].
In this study, we could not clearly determine whether CRC cells
treated with PAB died in mitosis or in interphase without using a
time-lapse microscopy approach. However, as cyclin B1 and p-
histone h3 (two indicator of mitosis) were expressed continuously
in CRC cells after PAB treatment even in situations where apoptosisFig. 2. PAB induces RKO and HCT-15 cell apoptosis. (A) RKO and HCT-15 cells were time-d
staining by ﬂow cytometry. Mean ± SD (n ¼ 3). **P < 0.01, ***P < 0.001. (B) Expressions of cle
western blot analysis. (C) The loss of MMP in RKO and HCT-15 cells was detected by JC-1 w
mitochondrial fractions in RKO and HCT-15 cells were extracted and expressions of cytochr
fraction. (E) Expressions of XIAP, MCL-1, BCL-2, BCL-XL and BAX in RKO and HCT-15 cells woccurred, most of CRC cells probably died in mitosis. Interestingly,
minor polyploidy cells could still be detected, indicating that some
cells slip into interphase after prolonged mitotic arrest. Cells that
slip into interphase either arrest at G1 phase and die lately if G1
checkpoint-related proteins such as p53 are functional or enter into
S phase, re-replicate their genomes and become polyploidy cells
[42,44]. Due to the p53 status is mutated in HCT-15 cells but not in
RKO cells, more polyploidy HCT-15 cells were detected than RKO
cells.
Previous studies revealed that PAB disrupted the microtubule of
HeLa cells by interacting with the colchicine binding site of tubulin
instead of the paclitaxel or vinca alkaloid binding site, leading toependently treated with PAB and cell apoptosis was detected with Annexin V-FITC/PI
aved-PARP, caspase3, caspase9 and caspase8 in RKO and HCT-15 cells were analyzed by
ith ﬂow cytometry. Mean ± SD (n ¼ 3). **P < 0.01, ***P < 0.001. (D) The cytosolic and
ome c were detected by western blot analysis. C: cytosolic fraction, M: mitochondrial
ere analyzed by western blot analysis.
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Fig. 5. CDK1 is involved in the effect of PAB to CRC cells. After 12 h PAB treatment, cells were treated with PAB in the absence and presence of RO-3306 or purvalanol A for 12 h and
36 h. (A) Expressions of p-histone h3 and (B) Expressions of cleaved-PARP and caspase3 were detected by western blot.
C. Wen et al. / Cancer Letters 383 (2016) 295e308 303microtubule destabilization [9,45]. Our experiments also showed
that PAB perturbedmicrotubule organization in CRC cells. Although
an interaction between PAB and the colchicine binding site of
tubulin was demonstrated, the afﬁnity of PAB for the colchicine
binding sitewas very low, indicating that a distinct PAB binding site
on tubulin may exist [9]. Therefore, besides the actively prolifer-
ating and aneuploid cancer cells are more prone to anti-mitotic
agents, a new tubulin binding site may also partially explain why
PAB can selectively inhibit cancer cells. Further studies should be
implemented to explore the new tubulin binding site of PAB and
mechanisms by which PAB selectively targets cancer cells. SeveralFig. 4. PAB induces the disruption of the microtubule and the activation of the SAC of CRC
apparatus were analyzed by immunoﬂuorescence microscopy after cells were stained for a-
abnormal spindle in 100 mitotic cells per experiment. Mean ± SD (n ¼ 3). ***P < 0.001. (B) H
in 100 mitotic cells per experiment. PM: prometaphase, M: metaphase, A þ T: anaphase ancell cycle checkpoints ensure the integrity of the cell genome, one
of which is the SAC in mitosis. The SAC is activated once the mitotic
apparatus is disturbed: The mitotic checkpoint complex (MCC),
including BUBR1, is ﬁrstly formed, and then the assembly of MCC
inhibits the anaphase-promoting complex/cyclosome (APC/C),
subsequently preventing the degradation of cyclin B1, the inacti-
vation of cyclin B1/CDK1 complex and the onset of anaphase
[29,46]. After prolonged mitotic arrest, cells either die in mitosis or
slip into interphase. These events together can be deemed as
mitotic catastrophe named by the 2012 Nomenclature Committee
on Cell Death [47,48]. In our experiments, PAB caused an increase incells. RKO and HCT-15 cells were treated with PAB for 12 h. (A) The mitotic spindle
tubulin (green) and DAPI (blue). Scale bar: 5 mm. Histograms display the percentage of
istograms display the percentage of prometaphase, metaphase and anaphase/telophase
d telophase. (C) Expression levels of BUBR1 were detected by western blot analysis.
Fig. 6. PAB induces proliferation inhibition and mitotic arrest in RKO/5FU-R and HCT-15/5FU-R cells. (A) The viability of RKO/5FU-R and HCT-15/5FU-R cells was measured by MTS
assay. (B) The colony formation of cells was counted after PAB-treated RKO/5FU-R and HCT-15/5FU-R cells were washed, ﬁxed and stained with crystal violet. Mean ± SD (n ¼ 3).
***P < 0.001. (C) RKO/5FU-R and HCT-15/5FU-R cells were stained with PI for DNA contents, followed by ﬂow cytometric analysis. Mean ± SD (n ¼ 3). *P < 0.05, **P < 0.01,
***P < 0.001. (D) Expression levels of cyclin B1 and p-histone h3 in RKO/5FU-R and HCT-15/5FU-R cells were detected by western blot analysis. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. PAB induces RKO/5FU-R and HCT-15/5FU-R cell apoptosis. (A) RKO/5FU-R and HCT-15/5FU-R cells were time-dependently treated with PAB and cell apoptosis was detected
with Annexin V-FITC/PI staining by ﬂow cytometry. Mean ± SD (n ¼ 3). **P < 0.01, ***P < 0.001. (B) The expression of cleaved-PARP, caspase3, caspase9 and caspase8 in RKO/5FU-R
and HCT-15/5FU-R cells were analyzed by western blot analysis. (C) The loss of MMP in RKO/5FU-R and HCT-15/5FU-R cells was detected by JC-1 with ﬂow cytometry. Mean ± SD
(n ¼ 3). *P < 0.05, **P < 0.01, ***P < 0.001. (D) The cytosolic and mitochondrial fractions in RKO/5FU-R and HCT-15/5FU-R cells were extracted and expressions of cytochrome c were
detected by western blot analysis. C: cytosolic fraction, M: mitochondrial fraction. (E) Expressions of XIAP, MCL-1, BCL-2, BCL-XL and BAX in RKO/5FU-R and HCT-15/5FU-R cells
were analyzed by western blot.
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Fig. 8. PAB inhibits both 5-FU-sensitive and -resistant CRC cells xenografts growth in vivo. Nude mice bearing 5-FU-sensitive and -resistant xenograft CRC were treated with vehicle
and PAB (50 mg/kg/d) for 22 days and 28 days in HCT-15 and HCT-15/5FU-R group, respectively. (A) and (D) Tumor growth curves and body weights were recorded every other days.
Mean ± SD (n ¼ 6). *P < 0.05. (B) Tumor tissues were weighed, imaged, and summarized from sacriﬁced mice. Mean ± SD (n ¼ 6). **P < 0.01. (C) Mitosis and apoptosis related
proteins in tumor tissues were detected by western blot analysis (HCT-15 control group: 1, 3, 5; HCT-15 PABetreated group: 12, 15, 16. HCT-15/5FU-R control group: 23, 25; 26; HCT-
15/5FU-R PABetreated group: 31, 34, 36). (E) Livers from sacriﬁced mice were ﬁxed in formalin overnight, processed for parafﬁn embedding, sectioned and stained by hematoxylin
and eosin. Scale bar: 100 mm.
Fig. 9. The schematic diagram of possible molecular mechanism of PAB-induced cytotoxicity in CRC cells.
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C. Wen et al. / Cancer Letters 383 (2016) 295e308 307abnormal spindle formation in mitotic CRC cells, which was barely
observed in the untreated group. Moreover, almost all CRC cells
were restricted in prometaphase and the expression of p-BUBR1
was signiﬁcantly up-regulated after 12 h of PAB treatment.
Apparently, PAB blocks mitotic progression in CRC cells by per-
turbing microtubule organization and activating the SAC. What's
more, PAB ultimately induced apoptotic cell death. The behaviors of
the CRC cells following PAB treatment to some extent conform to
the characteristics of mitotic catastrophe.
Activation of CDK1 is required for cells to enter mitosis from G2
phase. During mitosis, the CDK1 activity maintained by activation
of the SAC is vital before anaphase but the CDK1 inactivation is
needed for mitotic exit [29,49]. The activity of CDK1 is so important
in mitosis progression. Therefore, the role of CDK1 in the effect of
PAB on CRC cells was examined. In the current study, we showed
that PAB led to mitotic arrest in CRC cells, but the selective small-
molecule CDK1 inhibitor RO-3306 and purvalanol A could inhibit
the mitotic arrest induced by PAB, indicating that the activity of
CDK1 is involved in PAB-induced CRC cell mitotic arrest. Many anti-
mitotic drugs can cause mitotic arrest and initiate cell death.
However, the molecular signals by which anti-mitotic drugs induce
cell death remain poorly understood [27]. Recently, the role of
CDK1 in facilitating cell death by affecting the BCL-2 family proteins
was reported [30,50]. Our results showed that PAB induced
apoptosis in CRC cells, but RO-3306 and purvalanol A could
signiﬁcantly reduce PAB-induced apoptosis. This result indicates
that the activity of CDK1 plays an important role in PAB-induced
CRC cell apoptotic death. Nevertheless, more detailed mecha-
nisms should be evaluated to determine the action of CDK1 in PAB-
induced CRC cell mitotic arrest and apoptosis.
In this study, several unique aspects of PAB in the treatment of
CRC are shown. First, PAB inhibits the cell viability of a broad range
of genetically different CRC cell lines. Mechanisms underlying ef-
fects of PAB include the disruption of the CRC cell mitotic spindle
apparatus and the SAC activation, which maintain the activity of
CDK1 to induce mitotic arrest followed by caspase-dependent
apoptosis (Fig. 9). Moreover, PAB displays no signs of toxicity to
xenografts at tumor efﬁcacious doses and minimal cytotoxicity to
normal cells, indicating that PAB can selectively kill CRC cells.
Finally, PAB can overcome 5-FU resistance in CRC cells both in vitro
and in vivo. In conclusion, all these results show that PAB is a po-
tential candidate for CRC treatment.
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